Stifel Financial’s Enanta Pharmaceuticals ENTA Stock Holding History

Stifel Financial’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-14,429	Closed	-$319K	–	2417
2016 Q2	$319K	Sell	14,429 -694	-5%	-$18.2K	﹤0.01%	2010
2016 Q1	$445K	Buy	15,123 +558	+4%	+$15.5K	﹤0.01%	1644
2015 Q4	$481K	Buy	14,565 +2,305	+19%	+$75.1K	﹤0.01%	1687
2015 Q3	$443K	Sell	12,260 -479	-4%	-$20.6K	﹤0.01%	1629
2015 Q2	$573K	Buy	12,739 +190	+2%	+$7.39K	﹤0.01%	1619
2015 Q1	$384K	Buy	12,549 +3,709	+42%	+$144K	﹤0.01%	1763
2014 Q4	$450K	Buy	+8,840	New	+$396K	﹤0.01%	1660

Other funds holding ENTA

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stifel Financial's ENTA Position: Q3 2016 in Review

Stifel Financial sold out of Enanta Pharmaceuticals (ENTA) in Q3 2016, closing a stake of 14,429 shares — an estimated $319K sold.

Stifel Financial first reported a position in ENTA in Q4 2014 and held it in 7 quarters. The position peaked at $573K in Q2 2015. 136 funds tracked by Wall St. Rank hold ENTA as of Q3 2016.

Stifel Financial reported no remaining Enanta Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Stifel Financial sold 14,429 Enanta Pharmaceuticals shares in Q3 2016, an estimated $319K.
Stifel Financial first reported a position in Enanta Pharmaceuticals in Q4 2014 and held it in 7 quarters.
Stifel Financial's Enanta Pharmaceuticals position peaked at $573K in Q2 2015.
136 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2016.

Based on Stifel Financial's 13F filing for Q3 2016, filed 15 Nov 2016.